Ad-RTS-hIL-12 + Veledimex + Cemiplimab-Rwlc
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma
Trial Timeline
Aug 1, 2019 → Aug 5, 2021
NCT ID
NCT04006119About Ad-RTS-hIL-12 + Veledimex + Cemiplimab-Rwlc
Ad-RTS-hIL-12 + Veledimex + Cemiplimab-Rwlc is a phase 2 stage product being developed by Alaunos Therapeutics for Glioblastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04006119. Target conditions include Glioblastoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04006119 | Phase 2 | Terminated |
Competing Products
20 competing products in Glioblastoma